TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04837885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography computed tomography (PET/CT) with Intra-hepatic (IAH) injection
Description: Intra-hepatic injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection
Description: intravenous injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography computed tomography (PET/CT) with Intravenous (IV) injection
Description: intravenous injection of 68Ga-DOTA-peptides for targeted liver metastases in Positron emission tomography-computed tomography (PET/CT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUTATHERA® by intra-arterial hepatic (IAH) injection
Description: One treatment dose of LUTATHERA® by IAH injection for the 10 first patients with an PET/CT ratio greater then 3.~The LUTATHERA® by intra-arterial hepatic injection treatment is realised after the conventional treatment by 4 intravenous administrations

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scan
Description: Scans after completion of LUTATHERA® treatment injection
Study: NCT05762341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRESSURE INJURY PREVENTION TRAINING
Description: PREVENTION OF PRESSURE INJURY TO FACE TO FACE TRAINING

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRESSURE INJURY PREVENTION TRAINING
Description: PREVENTION OF PRESSURE INJURY TO FACE TO FACE TRAINING
Study: NCT04837911

Intervention type: DEVICE
Group type: OTHER
Intervention: Spirobank Smart
Description: Patients using the Spirobank Smart
Study: NCT06010810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 % Topical Tranexamic Acid
Description: Patient will be given 3% Topical Tranexamic Acid, on half of the face, twice a day for 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Topical Hidroquinone
Description: Patient will be given 4% Topical Hidroquinone, on half of the face, twice a day for 2 months
Study: NCT05942690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: manual osteopathic intervention
Description: The subject sits on the examination table for the manual osteopathic intervention. The expert osteopath, having no report from the sonographers, will manually test breathing diaphragmatic and will bring osteopathic manual treatment to the area of mobility restriction
Study: NCT06031688

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tepotinib
Description: Given PO
Study: NCT06585709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Active rTMS will be delivered with a MagVenture MagPro X100 rTMS device with a Cool-B65-AP coil. rTMS will be applied to a personalized treatment target within the Left-Dorsolateral Prefrontal Cortex using a Localite Neuronavigation device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Sham rTMS in an identical fashion to the active-rTMS condition will be delivered via the built-in e-sham system in the MagVenture device.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: High Ventral Striatal Reactivity
Description: We will test for ventral striatal reactivity using a Reassessment of Craving MRI task and define high ventral striatal reactivity as having \>mean voxels in the ventral striatum activate

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Low Ventral Striatal Reactivity
Description: We will test for ventral striatal reactivity using a Reassessment of Craving MRI task and define low ventral striatal reactivity as having \<mean voxels in the ventral striatum activate
Study: NCT06559215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: Patients will be randomized to receive Exparel intraoperatively via local infiltration. The dosage will be dependent on patient weight.
Study: NCT04687774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExaltTM Model D Single-Use Duodenoscope
Description: The Exalt™ Model D Single-Use Duodenoscope is a sterile, single-use endoscope that facilitates access to the duodenum, delivery of accessories, and live video when connected to an Exalt™ Controller.
Study: NCT04633252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months. For mCRPC patients: ADT will be continued as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months. For mCRPC patients: ADT will be continued as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months. For mCRPC patients: ADT will be continued as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: For mCSPC patients: Androgen Deprivation Therapy (ADT) may include GnRH agonist or monthly degarelix converted to GnRH agonist after 3 months. For mCRPC patients: ADT will be continued as per standard of care.
Study: NCT06340711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBP-301
Description: 2×10(12) viral particles per injection given intratumorally every 2 weeks for a total of 4 injections starting on Day 1 of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg IV given every 6 weeks starting on day 4 of the study and given for up to 2 years
Study: NCT05332951

Intervention type: OTHER
Intervention: Interpersonal Reactivity Index
Description: Questionnaire to be completed by the patient
Study: NCT06183788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote cognitive rehabilitation program
Description: Remote cognitive rehabilitation program will be performed through an online validated platform (Guttmann NeuroPersonalTrainer: https://gnpt.es/) run by the psychologists team. This is a Sanitary Product with CE certification (Sanitary Product RPS/430/2014; International Patent \[PCT/ES2008/00677\]) and here will be used within its approved indications. The rehabilitation program will increase in difficulty and decrease in frequency during the first year of follow-up (V1-V3).
Study: NCT05377242

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin (chemical C21H20O6) is derived from turmeric (Curcuma longa) root extract, standardized to contain 95% curcuminoids. The greatest obstacle with curcumin is its poor natural bioavailability. To help circumvent that issue, a piperazine is included as black pepper 5.3mg (Piper nigrum) fruit extract standardized to 95% piperine. The botanical we are using is provided by Pure Encapsulations. Curcumin being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug.~100 participants will be randomized to receive curcumin. Participants will receive placebo, low-dose (500 mg/day), medium-dose (1000 mg/day), and/or high dose (2000 mg/day) curcumin in a randomized order.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol (chemical C14H12O3) is provided as 99% Pure Trans-Resveratrol (MegaResveratrol) from polygonum cuspidatum root). Resveratrol being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug.~100 participants will be randomized to receive resveratrol. Participants will receive placebo, low-dose (250 mg/day), medium-dose (500mg/day), and/or high dose (1000mg/day) resveratrol in a randomized order.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stinging Nettle
Description: Stinging nettle is derived from nettle (Urtica spp) leaf. The botanical we are using is provided by Pure Encapsulations. Stinging Nettle being used in this study is a commercially available dietary supplement and is classified as food by the FDA instead of a drug.~100 participants will be randomized to receive stinging nettle. Participants will receive placebo, low-dose (435mg/day), medium-dose (870mg/day), and/or high dose (2610mg/day) stinging nettle in a randomized order.
Study: NCT05879055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM8002
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: IV infusion
Study: NCT06072768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15-day taper prednisone
Description: The 15-day taper group will assess the effect of an approximately 50% oral prednisone dose reduction over 15 days, and will be followed for an additional 15 days after the last dose reduction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150-day taper prednisone
Description: The 150-day taper group will assess the effect of reducing oral prednisone by 1 milligram (mg) every 30 days over 150 days, and will be followed for an additional 30 days after the last dose reduction.
Study: NCT05184335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brilaroxazine
Description: RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brilaroxazine
Description: RP5063, a new chemical entity (NCE), is a novel multimodal neuromodulator intended for treating schizophrenia and comorbid conditions. This drug is an investigational drug and has not been approved for treatment or marketing. RP5063 belongs to a class of third generation antipsychotics called Dopamine-Serotonin System Stabilizers. The chemical name of the RP5063 active pharmaceutical ingredient (API) is 6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo\[b\]\[1,4\]oxazin-3(4H)-one hydrochloride.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: RP5063 matching Placebo
Study: NCT05877261

Intervention type: DEVICE
Intervention: Cementless Total Knee Replacement
Description: Artificial knee implant inserted by cementless fixation.
Study: NCT05642780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: be administrated as an intravenous (IV) infusion on Day 1,15, 29 of each 42-day cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: be administrated as an intravenous (IV) infusion on Day 1 of each 42-day cycle;
Study: NCT05934019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMPATIA 1
Description: The internet-program EMPATIA is hosted on a secure website https://selfhelp.psy.unibe.ch run by the Faculty of Human Sciences and is accessible from any regular internet browser. The software is not CE-marked as it has been developed for research purposes only. EMPATIA consists of 8 sessions and 1 booster session 3 weeks after the last session. It targets transdiagnostic mechanisms that have been identified in several mental disorders in adolescents: behavioral avoidance, repetitive negative thinking including intolerance of uncertainty, emotion, self-critical perfectionism and rejection sensitivity. The contents of EMPATIA are evidence-based and well-established cognitive-behavioral interventions dedicated to the respective transdiagnostic mechanism. The self-help program consists of psychoeducation, cognitive restructuring, relaxation and acceptance-based interventions, exposure and behavioral experiments and behavioral activation as treatment components.
Study: NCT05517447

Intervention type: OTHER
Group type: OTHER
Intervention: Observational cohort study
Description: Observational cohort study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Study: NCT06429007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Infants in the study will receive 50% of the target dose (12.5mg/kg) for the first 6 weeks of participation. At the 6 week visit, the patient will be assessed and if found still eligible, will receive the full dose (25mg/kg) for the remaining 6 weeks of participation.
Study: NCT05429476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Plasminogen Activator (Alteplase)
Description: Tissue Plasminogen Activator (Alteplase) 0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour~Other Names:~Actilyse Activase tPA r-tPA
Study: NCT05262530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT142
Description: Intravenous bolus/infusion
Study: NCT05459571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally or intravenously
Study: NCT06447922

Intervention type: OTHER
Intervention: Metal ion level testing
Description: Patients will undergo a pre- and post-operative blood draw to analyze metal ion levels (Cobalt, Chromium, Titanium and Nickel)

Intervention type: OTHER
Intervention: Metal ion level testing
Description: Patients will undergo a pre- and post-operative blood draw to analyze metal ion levels (Cobalt, Chromium, Titanium and Nickel)
Study: NCT06562114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TML-6 Granules
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT05918835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (active rTMS)
Description: HF-rTMS is applied with a figure-of-8 coil using the Magstim TMS System. Participants receive one administration of HF-rTMS, delivered to the region of the right dorsolateral prefrontal cortex (DLPFC) with greatest resting-state functional connectivity to the dorsal striatum (individualized per participant). HF-rTMS is delivered at a frequency of 10 Hz for approximately 37 minutes (3000 total pulses).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation (sham rTMS)
Description: Sham rTMS is applied with a figure-of-8 sham coil using the Magstim TMS System, which is identical to the active coil, replicates the sounds of HF-rTMS, and is designed to mimic sensations of HF-rTMS. Participants receive one administration of sham rTMS, delivered to the region of the right dorsolateral prefrontal cortex (DLPFC) with greatest resting-state functional connectivity to the dorsal striatum (individualized per participant). Sham rTMS is delivered for approximately 37 minutes (3000 total pulses).
Study: NCT05718700

Intervention type: DRUG
Intervention: Bulevirtide
Description: Administered via subcutaneous (SC) injections

Intervention type: DRUG
Intervention: Bulevirtide
Description: Administered via subcutaneous (SC) injections
Study: NCT05859425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time rehabilitative ultrasound imaging (RUSI)
Description: Τhe ultrasound equipment used was B-K Μedical Mini Focus 1402 equipped with high frequency linear probe (8670, 5-12MHz) using standard musculoskeletal settings and the software: V 1.01.01.137. Ultrasound gel (AQUASONIC® 100, Parker Inc., Orange, NJ) was used as coupling agent. TrA imaging was initially performed with participants in crook lying, with the US head positioned along the lateral abdominal wall with reference points at the lower point of the rib cage (last rib) and the anterior superior iliac spine, on the right side of the person, midway between these two points. The US head was moved until tester (investigator) had the best possible visualization of the lateral abdominal muscles (external oblique, internal oblique and TrA). During the execution of the exercises, the participants could watch the ultrasound screen along with the therapist's guidance, thus receiving information (US-visual feedback) of their TrA activation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tactile feedback (control intervention)
Description: Palpatory-guided (manual) feedback for TrA activation
Study: NCT06324825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzhegn Nizeng Decoction
Description: Subjects taking prepared Fuzhegn Nizeng granules twice daily for 6 month.
Study: NCT05023005

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Strain-Counterstrain treatment of piriformis muscle
Description: Participant will lay prone on table with affected leg close to edge of table. Piriformis muscle tender point is identified and palpated. Then patient leg is passively moved off table and passive hip flexion, abduction, and possible internal/external rotation is added to reduce tender point by 70% or more. This is done passively. This position is held for 90 seconds and then participant is passively returned back to neutral prone position with leg on table. Tender point is palpated again to reassess for change in pain (using subjective visual analog scale). An algometer is also used pre and post to assess objective change in pressure pain threshold.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strain-Counterstrain treatment of piriformis muscle
Description: Participant will lay prone on table with affected leg close to edge of table. Piriformis muscle tender point is identified and palpated. Then patient leg is passively moved off table and passive hip flexion, abduction, and possible internal/external rotation is added to reduce tender point by 70% or more. This is done passively. This position is held for 90 seconds and then participant is passively returned back to neutral prone position with leg on table. Tender point is palpated again to reassess for change in pain (using subjective visual analog scale). An algometer is also used pre and post to assess objective change in pressure pain threshold.
Study: NCT04757363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: regorafenib (80 mg on days 1-21 of the 28-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: nivolumab (240 mg on days 1 and 15 of the 28-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy with oxaliplatin
Description: FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h).
Study: NCT05539170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate positive parenting feedback
Description: Individual positive feedback concerning their parenting and their child's behavior.
Study: NCT06279923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-BAFF Targeted CAR T-cells
Description: Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion
Study: NCT04902248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The OTSC® System Set
Description: The endoscope was extracted and equipped with the OTSC system. OTSC system is deployed on the lesion with suction to target lesion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angiographic embolization
Description: Transcatheter selective embolization to bleeding arteries
Study: NCT04329806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.2 MG
Description: Moxonidine 0.2 MG twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5 MG
Description: Amlodipine 5 MG twice daily
Study: NCT06324825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moluodan granules
Description: Subjects taking prepared Moluodan granules 9g twice daily for 6 month.
Study: NCT05413460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acupoint stimulation
Description: Electrodes are placed at acupoints and connected to the stimulator. Electrical stimulation is given during surgery.